Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.6M | $9.9M | $18.4M | $13.5M | $38.2M | $27.4M | $40.7M |
| Cost of revenue | $0 | $0 | $0 | $0 | $1.5M | $7.7M | $6.2M | $9.1M |
| Gross profit | $0 | $1.6M | $9.9M | $18.4M | $12.0M | $30.5M | $21.2M | $31.7M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 89.0% | 79.8% | 77.4% | 77.7% |
| R&D | $464.6K | $2.4M | $1.7M | $3.2M | $8.5M | $9.1M | $9.2M | $16.8M |
| Operating income | −$11.3M | −$6.9M | −$7.7M | $7.1M | −$21.2M | $10.9M | −$2.2M | $5.2M |
| EBITDA | −$11.3M | −$7.0M | −$7.8M | $7.1M | −$21.1M | $11.1M | −$1.5M | $5.8M |
| Net income | −$11.5M | −$7.0M | −$7.8M | $6.6M | −$21.2M | $11.6M | −$1.9M | $3.0M |
| Net margin | — | -454.1% | -78.9% | 35.7% | -156.8% | 30.3% | -6.8% | 7.4% |
| EPS (diluted) | -6.57 | -3.88 | -4.09 | 2.94 | -7.10 | 2.17 | -0.44 | 0.51 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds OPNT.
No tracked institution reports a position in OPNT as of their last filing.
| Execution date | Ratio |
|---|---|
| 2009-08-20 | 20-for-1 |
No one on the platform has traded OPNT yet.
| $121M |
| — |
| HLVXHilleVax, Inc. | $2.09 | -0.48% | $105M | — |
| JNCEJounce Therapeutics, Inc. | $1.88 | +0.00% | $99M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$OPNT The deal was $20 pee share plus up to $8 in milestones, right? Where are we with the milestones?
View on StockTwits ↗$OPNT Still want to know why we sold so cheaply???
View on StockTwits ↗$OPNT STILL pissed off we sold so cheaply :( On Wednesday, the FDA announced that Emergent Biosciences will extend the shelf-life of Narcan 4 milligram (mg) naloxone hydrochloride nasal spray products from 3-years to 4-years. The extension request is the latest of multiple steps that the FDA has taken to reduce overdose-related deaths.
View on StockTwits ↗$OPNT $HRTX So Collard featured 3 times with the FDA last week.....at least he is a part of OPIANT's story
View on StockTwits ↗$OPNT still pissed this sold.so cheaply seems criminal:(
View on StockTwits ↗$OPNT Considering that officer and paramedic carry nalaxone there sure to carry out product too.
View on StockTwits ↗$OPNT 800k police officers and 170k paramedics at $75 we can generate $70m revenue in USA alone let alone Europe and the rest of the markets.
View on StockTwits ↗$OPNT too bad we cant buy or sell on this damn stock!! Shes a dead cat!
View on StockTwits ↗$OPNT https://www.fda.gov/news-events/press-announcements/fda-approves-prescription-nasal-spray-reverse-opioid-overdose
View on StockTwits ↗$OPNT is this stock dead? no movement all day! dont have a position in this one. waiting on PDUFA approval before jumping in supposed to be today. BPMC just got approved.
View on StockTwits ↗$OPNT this was to be our PDUFA date week. Well, perhaps we’ll get something from the CVrs.
View on StockTwits ↗@iamabearbull He does this on the regular according to Bio. Involved in multiple companies. Net worth on net says nearing $20 mil- betting a lot more on paper. Company he’s also involved with- Opiant Pharmaceuticals $OPNT traded for near $40 Jan 2022, dipped to $7’s late summer, sold in Nov 2022 for $20 a share- Longs seemed more than pissed. May be great news for those getting in now at these levels, but I believe dies not bode well for any longs here with double digit avg. Time will tell.. some here thing 12-24 months.
View on StockTwits ↗$OPNT have any of you OG’s moved your money over to $EBS yet? I’d love to get your thoughts.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.